Wiley. 7 (1): 501–523. doi:10.1111/j.1743-6109.2009.01626.x. PMID 20092450. External links

Erectile dysfunction at Curlie
Legal status
In November 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Lumykras, intended for the treatment of people with KRAS G12C mutation non-small cell lung cancer (NSCLC). The applicant for this medicinal product is Amgen Europe B.V. Sotorasib was approved for medical use in the European Union in January 2022. Names
Sotorasib is the recommended international nonproprietary name (INN). References
Further reading
Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI,  et al. (September 2020). "KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors". N Engl J Med. 383 (13): 1207–17. doi:10.1056/NEJMoa1917239. PMC 7571518. PMID 32955176. Lanman BA, Allen JR, Allen JG, Amegadzie AK, Ashton KS, Booker SK,  et al. (January 2020). "Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors". J Med Chem. 63 (1): 52–65. doi:10.1021/acs.jmedchem.9b01180. PMID 31820981. External links
"Sotorasib". Drug Information Portal. U.S. National Library of Medicine. Clinical trial number NCT03600883 for "A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)" at ClinicalTrials.gov